Lisanti Capital Growth LLC Has $3.91 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Lisanti Capital Growth LLC decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 31.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 77,665 shares of the biotechnology company’s stock after selling 35,490 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Corcept Therapeutics were worth $3,914,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CORT. Jacobs Levy Equity Management Inc. increased its position in Corcept Therapeutics by 40.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after purchasing an additional 352,947 shares in the last quarter. Braun Stacey Associates Inc. acquired a new position in shares of Corcept Therapeutics during the fourth quarter worth $14,935,000. FMR LLC lifted its stake in shares of Corcept Therapeutics by 24.6% in the 3rd quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock valued at $63,122,000 after acquiring an additional 269,074 shares during the last quarter. Synergy Asset Management LLC boosted its holdings in shares of Corcept Therapeutics by 131.3% during the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after acquiring an additional 262,503 shares in the last quarter. Finally, M&G PLC bought a new stake in Corcept Therapeutics during the 3rd quarter worth $11,173,000. Institutional investors own 93.61% of the company’s stock.

Insider Activity

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,827 shares of company stock worth $2,688,486 in the last quarter. 20.50% of the stock is owned by corporate insiders.

Corcept Therapeutics Stock Performance

Shares of CORT opened at $54.30 on Friday. The stock has a market capitalization of $5.73 billion, a P/E ratio of 43.10 and a beta of 0.58. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $60.27 and its two-hundred day simple moving average is $52.00. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $75.00.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. As a group, analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Canaccord Genuity Group lifted their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. Piper Sandler upped their price target on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. StockNews.com cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $115.00 price target on shares of Corcept Therapeutics in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.